Disc Medicine (NASDAQ:IRON) Receives Outperform Rating from Wedbush

Disc Medicine (NASDAQ:IRON - Get Free Report)'s stock had its "outperform" rating reiterated by analysts at Wedbush in a research note issued to investors on Monday,RTT News reports. They presently have a $90.00 price objective on the stock. Wedbush's price target would indicate a potential upside of 72.84% from the company's previous close.

IRON has been the subject of several other reports. TD Cowen assumed coverage on Disc Medicine in a research note on Thursday, February 27th. They issued a "buy" rating for the company. Cantor Fitzgerald raised their price objective on Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a research note on Tuesday, March 18th. Scotiabank increased their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, March 3rd. BMO Capital Markets raised their price target on shares of Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research report on Monday, May 12th. Finally, Raymond James began coverage on shares of Disc Medicine in a research report on Wednesday, June 11th. They issued a "strong-buy" rating and a $89.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $96.70.

Disc Medicine Trading Down 3.1%

IRON stock traded down $1.64 during trading on Monday, reaching $52.07. 138,041 shares of the stock were exchanged, compared to its average volume of 347,833. The firm's 50 day moving average is $45.86 and its 200 day moving average is $53.19. The firm has a market cap of $1.80 billion, a P/E ratio of -13.07 and a beta of 0.73. Disc Medicine has a twelve month low of $30.82 and a twelve month high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03). As a group, analysts predict that Disc Medicine will post -4.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider William Jacob Savage sold 2,996 shares of the company's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $50.00, for a total transaction of $149,800.00. Following the sale, the insider now directly owns 56,725 shares in the company, valued at approximately $2,836,250. This represents a 5.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Mona Ashiya sold 5,738 shares of the firm's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $54.11, for a total value of $310,483.18. Following the completion of the transaction, the director now directly owns 186,541 shares of the company's stock, valued at $10,093,733.51. The trade was a 2.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 67,178 shares of company stock valued at $3,582,568 over the last ninety days. 4.24% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. purchased a new position in Disc Medicine during the first quarter worth about $78,288,000. FMR LLC boosted its position in shares of Disc Medicine by 358.7% during the 4th quarter. FMR LLC now owns 1,866,248 shares of the company's stock valued at $118,320,000 after acquiring an additional 1,459,434 shares during the last quarter. Siren L.L.C. purchased a new position in shares of Disc Medicine during the first quarter worth about $53,207,000. Wellington Management Group LLP increased its position in shares of Disc Medicine by 67.9% in the first quarter. Wellington Management Group LLP now owns 2,343,499 shares of the company's stock worth $116,331,000 after purchasing an additional 948,094 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Disc Medicine by 62.4% in the fourth quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company's stock worth $77,170,000 after purchasing an additional 467,988 shares during the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.